The clinical data (especially the resection) met and exceeded the requirements of the trial. I do not understand how they can now change their minds or the goalposts. These are sick patients. To be able to undergo surgery when it was initially inoperable is very beneficial.
This committee are unbelievable.
OSL is going to challenge their findings.
Ann: CE Marking Update, page-12
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.97M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $25.28K | 1.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4747126 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 6365956 | 17 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| OSL (ASX) Chart |